Idiopathic hypogonadotropic hypogonadism in a male runner is reversed by clomiphene citrate.
To assess the efficacy of estrogen antagonist therapy on the function of the hypothalamic-pituitary-testicular axis in a young male runner with significant morbidity attributable to idiopathic hypogonadotropic hypogonadism. An uncontrolled case study. The outpatient endocrinology clinic of a university tertiary referral center. A 29-year-old male who has run 50 to 90 miles per week since 15 years of age and who presented with a pelvic stress fracture, markedly decreased bone mineral density, and symptomatic hypogonadotropic hypogonadism. Clomiphene citrate (CC) at doses up to 50 mg two times per day over a 5-month period. Serum concentrations of LH, FSH, and T before and after CC therapy, as well as clinical indicators of gonadal function. Barely detectable levels of LH and FSH associated with hypogonadal levels of T were restored to the normal range with CC therapy. The patient experienced improved erectile function, increased testicular size and sexual hair growth, and an improved sense of well being. Exercise-induced hypogonadotropic hypogonadism exists as a clinical entity among male endurance athletes, and CC may provide a safe and effective treatment option for males with debilitating hypogonadism related to endurance exercise.